TNGX (Tango Therapeutics) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNGX Tango Therapeutics Inc TNGX
54 GF Score
Price $27.06
GF Value $9.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Tango Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

TNGX vs LEGN, CAI, EWTX: Short Interest Comparison

For the Biotechnology subindustry, Tango Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tango Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Tango Therapeutics's Short Interest falls into.


TNGX
54GF Score
Tango Therapeutics Inc TNGX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tango Therapeutics (TNGX) Overvalued in 2026?

Based on GuruFocus' analysis, Tango Therapeutics stock appears to be overvalued. The current stock price of $27.06 is trading 172.7% above its estimated GF Value™ of $9.92. GuruFocus considers Tango Therapeutics to be Significantly Overvalued.

Key valuation signals for TNGX:

  • Short Interest:
  • GF Value™: $9.92 vs. price of $27.06 (172.7% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the TNGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tango Therapeutics Business Description

Address 201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
54GF Score

Get the complete analysis for TNGX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.06
Price
$9.92
GF Value